REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
https://doi.org/10.21518/2079-701X-2017-14-6-10
Abstract
Development of new effective drugs for therapy of metastatic melanoma (BRAF/MEK inhibitors, PD1/CTLA4 blockers) requires additional studies of the optimal sequence of their use. But in many cases the duration of the effect of these medicinal products is limited by time even in their sequential use. This literature review considers a possibility of repeated indication of BRAF/ MEK inhibitors after progression on them in various clinical settings. The potential use of such approach is illustrated by two own clinical observations.
About the Authors
I. V. Samoylenko
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
PhD in medicine
Y. A. Zhulikov
Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
L. V. Demidov
Blokhin National Medical Research Center of Oncology of the Ministry of Health of Russia
Russian Federation
Russian Federation
MD, Prof.
References
1. Balch CM, Gershenwald JE, Soong SJ et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol, 2009, 27(36): 6199-6206.
2. Oda N, Ichihara E, Hotta K et al. Phase II Study of the EGFR-TKI Rechallenge With Afatinib in Patients With Advanced NSCLC Harboring Sensitive EGFR Mutation Without T790M: Okayama Lung Cancer Study Group Trial OLCSG 1403. Clin Lung Cancer, 2017, 18(2): 241-244.
3. Goldie JH, Coldman AJ. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep, 1979, 63(11-12): 1727-1733.
4. Greaves M, Maley CC. Clonal evolution in cancer. Nature, 2012, 481(7381): 306-313.
5. Sun C, Wang L, Huang S et al. Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma. Nature, 2014, 508(7494): 118-122.
6. Johnson DB, Menzies AM, Zimmer L et al. Acquired BRAF inhibitor resistance: A multi-center meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanisms. Eur J Cancer, 2015, 51(18): 2792-2799.
7. Romano E, Pradervand S, Paillusson A et al. Identification of multiple mechanisms of resistance to vemurafenib in a patient with BRAFV600E-mutated cutaneous melanoma successfully rechallenged after progression. Clin Cancer Res, 2013, 19(20): 5749-5757.
8. Sanchez-Laorden B, Viros A, Girotti MR et al. BRAF inhibitors induce metastasis in RAS mutant or inhibitor-resistant melanoma cells by reactivating MEK and ERK signaling. Sci Signal, 2014, 7(318): ra30.
9. Johnson DB, Flaherty KT, Weber JS et al. Combined BRAF (Dabrafenib) and MEK inhibition (Trametinib) in patients with BRAFV600mutant melanoma experiencing progression with single-agent BRAF inhibitor. J Clin Oncol, 2014, 32(33): 3697-3704.
10. Ribas A, Gonzalez R, Pavlick A, Hamid O, Gajewski TF, Daud A, Flaherty L, Logan T, Chmielowski B, Lewis K et al. Combination of vemurafenib and cobimetinib in patients with advanced BRAF(V600)-mutated melanoma: a phase 1b study. The Lancet Oncology, 2014, 15(9): 954-965.
11. Schreuer M, Jansen Y, Planken S et al. Combination of dabrafenib plus trametinib for BRAF and MEK inhibitor pretreated patients with advanced BRAF(V600)-mutant melanoma: an open-label, single arm, dual-centre, phase 2 clinical trial. Lancet Oncol, 2017, 18(4): 464-472.
12. Roux J, Pages C, Malouf D et al. BRAF inhibitor rechallenge in patients with advanced BRAF V600-mutant melanoma. Melanoma Res, 2015, 25(6): 559-563.
13. Rogiers A, Wolter P, Bechter O. Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination. Melanoma Res, 2017, 27(2): 164-167.
14. Amann VC, Hoffmann D, Mangana J, Dummer R, Goldinger SM. Successful retreatment with combined BRAF/MEK inhibition in metastatic BRAFV600-mutated melanoma. J Eur Acad Dermatol Venereol, 2017.
Review
For citations:
Samoylenko IV, Zhulikov YA, Demidov LV. REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION. Meditsinskiy sovet = Medical Council. 2017;(14):6-10. (In Russ.) https://doi.org/10.21518/2079-701X-2017-14-6-10
Views:
616
Email this article 